IL307991A - 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression - Google Patents

19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression

Info

Publication number
IL307991A
IL307991A IL307991A IL30799123A IL307991A IL 307991 A IL307991 A IL 307991A IL 307991 A IL307991 A IL 307991A IL 30799123 A IL30799123 A IL 30799123A IL 307991 A IL307991 A IL 307991A
Authority
IL
Israel
Prior art keywords
compound
ham
total score
anxiety
depressive disorder
Prior art date
Application number
IL307991A
Other languages
English (en)
Hebrew (he)
Inventor
Robert Alfonso Lasser
James Doherty
Jeffrey Martin Jonas
Stephen Jay Kanes
Handan Gunduz-Bruce
Helen Anne Colquhoun
Ryan Arnold
Vijayveer Bonthapally
Joi Lisa Dunbar
Bambang Senoaji Adiwijaya
Original Assignee
Sage Therapeutics Inc
Robert Alfonso Lasser
James Doherty
Jeffrey Martin Jonas
Stephen Jay Kanes
Gunduz Bruce Handan
Helen Anne Colquhoun
Ryan Arnold
Vijayveer Bonthapally
Joi Lisa Dunbar
Bambang Senoaji Adiwijaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc, Robert Alfonso Lasser, James Doherty, Jeffrey Martin Jonas, Stephen Jay Kanes, Gunduz Bruce Handan, Helen Anne Colquhoun, Ryan Arnold, Vijayveer Bonthapally, Joi Lisa Dunbar, Bambang Senoaji Adiwijaya filed Critical Sage Therapeutics Inc
Publication of IL307991A publication Critical patent/IL307991A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL307991A 2021-04-29 2022-04-29 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression IL307991A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US202163289506P 2021-12-14 2021-12-14
US202163289520P 2021-12-14 2021-12-14
US202263298601P 2022-01-11 2022-01-11
PCT/US2022/026920 WO2022232504A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Publications (1)

Publication Number Publication Date
IL307991A true IL307991A (en) 2023-12-01

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307991A IL307991A (en) 2021-04-29 2022-04-29 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression

Country Status (11)

Country Link
US (1) US20240216395A1 (https=)
EP (1) EP4329770A1 (https=)
JP (2) JP2024515829A (https=)
KR (1) KR20240006026A (https=)
AU (1) AU2022266680A1 (https=)
BR (1) BR112023022264A2 (https=)
CA (1) CA3218072A1 (https=)
IL (1) IL307991A (https=)
MX (1) MX2023012727A (https=)
TW (1) TW202308654A (https=)
WO (1) WO2022232504A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021006985A (es) * 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
IL315023A (en) * 2022-02-16 2024-10-01 Sage Therapeutics Inc Neuroactive steroids for treatment of cns-related disorders

Also Published As

Publication number Publication date
JP2024515829A (ja) 2024-04-10
US20240216395A1 (en) 2024-07-04
TW202308654A (zh) 2023-03-01
MX2023012727A (es) 2023-11-08
KR20240006026A (ko) 2024-01-12
WO2022232504A1 (en) 2022-11-03
JP2025111701A (ja) 2025-07-30
CA3218072A1 (en) 2022-11-03
BR112023022264A2 (pt) 2024-01-23
EP4329770A1 (en) 2024-03-06
AU2022266680A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
IL307991A (en) 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression
Koçer et al. Effect of the route of administration of methylprednisolone on oedema and trismus in impacted lower third molar surgery
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
IL315023A (en) Neuroactive steroids for treatment of cns-related disorders
JP2016540738A5 (https=)
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
CA2558896A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AU2017261303A1 (en) Ophthalmic compositions
MX2024015063A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades
MX2009003750A (es) Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
MY210324A (en) 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING a-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
WO2023250247A3 (en) R-mdma crystal forms
JP2018526460A5 (https=)
Bin Rubaia’an et al. Cortisol in oral and maxillofacial surgery: A double‐edged sword
Krishnan Role of corticosteroids in oral and maxillofacial surgery
IL274512B2 (en) IgG-stimulated remodeling of peripheral nerve myelin
WO2020170030A3 (en) Method for providing early onset of action in the treatment of rosacea
De Benedetti et al. FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial
Waltrip et al. A pilot study to determine the feasibility of continuous cefazolin infusion
Lee et al. Short-term intraocular pressure trends after intravitreal triamcinolone injection
IL320111A (en) Cnp compounds
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
WO2023019095A3 (en) Momelotinib combination therapy